Prosecution Insights
Last updated: October 04, 2026

Neurodex Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Neurodex Inc. holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 1 pending office action. This single action is the only active procedural requirement for the company at this time.

The prosecution is being conducted by 1 distinct examiner in 1 distinct art unit. With 1 pending office action assigned to 1 examiner, the company's current patenting activities are highly focused. This structure simplifies the management of the portfolio by limiting the number of distinct examiner interactions and technical divisions involved.

CHERNYSHEV, OLGA N is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner is the sole individual responsible for the company's current pending workload. The company's prosecution strategy must address the specific requirements of this examiner within the 1 distinct art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
0
Medium (0%)
1
Easy (100%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§112 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHERNYSHEV, OLGA N 1 54.5% +34.4%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18245140 DIAGNOSTIC ASSAYS EMPLOYING NEURON-DERIVED EXOSOMES CHERNYSHEV, OLGA N —

Top Art Units

Art UnitApps
1675 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18245140 DIAGNOSTIC ASSAYS EMPLOYING NEURON-DERIVED EXOSOMES CHERNYSHEV, OLGA N 1675 §112 Non-Final OA — Pending Mar 13, 2023

Managing Neurodex Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month